Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

VIALE-M: This phase III trial has been designed to evaluate the addition of two cancer treatments (venetoclax in combination with azacitidine) to standard care, compared with standard care on its' own as a maintenance therapy for adult's with acute myeloid leukaemia (AML)Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible patients will be randomised to receive up to 24-cycles of best standard care, as prescribed by their doctor, alone or in addition to up to 24-cycles of venetoclax and up to 6-cylce of azacitadine.

Age

People 18+

Phase

III

Trial Acronym

VIALE-M

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04102020
M19-708, CT1319

Commercial Sponsor

AbbVie

Scientific Title

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Share with email